MA49137A - Amides de pyridone deutérés et leurs promédicaments utilisés en tant que modulateurs de canaux sodiques - Google Patents
Amides de pyridone deutérés et leurs promédicaments utilisés en tant que modulateurs de canaux sodiquesInfo
- Publication number
- MA49137A MA49137A MA049137A MA49137A MA49137A MA 49137 A MA49137 A MA 49137A MA 049137 A MA049137 A MA 049137A MA 49137 A MA49137 A MA 49137A MA 49137 A MA49137 A MA 49137A
- Authority
- MA
- Morocco
- Prior art keywords
- deuterated
- sodium channel
- channel modulators
- predictions used
- pyridone amides
- Prior art date
Links
- -1 DEUTERATED PYRIDONE AMIDES Chemical class 0.000 title 1
- 108010052164 Sodium Channels Proteins 0.000 title 1
- 102000018674 Sodium Channels Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762507172P | 2017-05-16 | 2017-05-16 | |
| US201762547718P | 2017-08-18 | 2017-08-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49137A true MA49137A (fr) | 2021-04-21 |
Family
ID=62567801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049137A MA49137A (fr) | 2017-05-16 | 2018-05-16 | Amides de pyridone deutérés et leurs promédicaments utilisés en tant que modulateurs de canaux sodiques |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11358977B2 (fr) |
| EP (1) | EP3625214B1 (fr) |
| JP (1) | JP7104070B2 (fr) |
| KR (1) | KR102714561B1 (fr) |
| CN (1) | CN110740993B (fr) |
| AU (1) | AU2018271110A1 (fr) |
| BR (1) | BR112019024016A2 (fr) |
| CA (1) | CA3063901A1 (fr) |
| CL (1) | CL2019003239A1 (fr) |
| CO (1) | CO2019013021A2 (fr) |
| ES (1) | ES2927712T3 (fr) |
| IL (1) | IL270680B (fr) |
| MA (1) | MA49137A (fr) |
| MX (1) | MX390793B (fr) |
| UA (1) | UA124857C2 (fr) |
| WO (1) | WO2018213426A1 (fr) |
| ZA (1) | ZA201907619B (fr) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11529337B2 (en) | 2018-02-12 | 2022-12-20 | Vertex Pharmaceuticals Incorporated | Method of treating pain |
| JP7288051B2 (ja) | 2018-11-02 | 2023-06-06 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｎａｖ１．８阻害薬としての２－アミノ－Ｎ－ヘテロアリール－ニコチンアミド類 |
| US20220073471A1 (en) * | 2019-01-04 | 2022-03-10 | Jiangsu Hengrui Medicine Co., Ltd. | 6-oxo-1,6-dihydropyridazine derivative, preparation method therefor and medical use thereof |
| US12440481B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| WO2020146682A1 (fr) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides utilisés en tant que modulateurs de canaux sodiques |
| TW202043200A (zh) * | 2019-01-25 | 2020-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | ２－側氧基－１，２－二氫吡啶類衍生物、其製備方法及其在醫藥上的應用 |
| WO2020169042A1 (fr) * | 2019-02-20 | 2020-08-27 | 江苏恒瑞医药股份有限公司 | Dérivé de promédicament de 6-oxo -1,6-dihydropyridazine, son procédé de préparation et son application en médecine |
| WO2020206119A1 (fr) * | 2019-04-02 | 2020-10-08 | Vertex Pharmaceuticals Incorporated | Procédé de production d'amides de pyridone et de promédicaments associés utiles en tant que modulateurs de canaux sodiques |
| WO2020219867A1 (fr) * | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Compositions de co-cristaux d'amide de pyridone pour le traitement de la douleur |
| WO2021011513A1 (fr) | 2019-07-16 | 2021-01-21 | Bristol-Myers Squibb Company | Promédicaments servant à la modulation de l'interleukine |
| WO2021018165A1 (fr) * | 2019-07-30 | 2021-02-04 | 江苏恒瑞医药股份有限公司 | Dérivé pyridine benzamide, son procédé de préparation, et ses applications médicales |
| WO2021032074A1 (fr) * | 2019-08-19 | 2021-02-25 | 江苏恒瑞医药股份有限公司 | Dérivé cyclicque aromatique condensé de benzamide, son procédé de préparation et son utilisation en médecine |
| BR112022010924A2 (pt) | 2019-12-06 | 2022-09-06 | Vertex Pharma | Tetra-hidrofuranos substituídos como moduladores de canais de sódio |
| CN114437062B (zh) * | 2020-04-30 | 2024-05-17 | 成都海博为药业有限公司 | 一种可作为钠通道调节剂的化合物及其用途 |
| US12516046B2 (en) | 2020-06-17 | 2026-01-06 | Merck Sharp & Dohme Llc | 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors |
| US11802122B2 (en) | 2020-06-17 | 2023-10-31 | Merck Sharp & Dohme Llc | 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors |
| CN113880771B (zh) * | 2020-07-03 | 2023-09-19 | 福建盛迪医药有限公司 | 一种选择性Nav抑制剂的结晶形式及其制备方法 |
| WO2022037647A1 (fr) * | 2020-08-19 | 2022-02-24 | 江苏恒瑞医药股份有限公司 | Forme cristalline d'inhibiteur sélectif de nav et son procédé de préparation |
| TW202214259A (zh) * | 2020-08-19 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種選擇性ＮａＶ抑制劑的前藥及其晶型 |
| CN111808019B (zh) * | 2020-09-08 | 2020-11-27 | 上海济煜医药科技有限公司 | 一种并环化合物及其应用 |
| CN116601153B (zh) * | 2020-12-18 | 2025-10-28 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为nav1.8抑制剂的含氮2,3-二氢喹唑啉酮化合物 |
| EP4262978A1 (fr) * | 2020-12-18 | 2023-10-25 | GlaxoSmithKline Intellectual Property Development Limited | Composés chimiques utiles pour inhiber les canaux sodiques sensibles à la tension nav1.8 et traiter les maladies médiées par nav1.8 |
| WO2022179624A1 (fr) * | 2021-02-26 | 2022-09-01 | 江苏恒瑞医药股份有限公司 | Sel pharmaceutiquement acceptable d'un inhibiteur sélectif de nav et forme cristalline de ce dernier, et procédé de préparation associé |
| GEP20257795B (en) | 2021-05-07 | 2025-09-25 | Merck Sharp & Dohme Llc | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
| SMT202500481T1 (it) | 2021-06-04 | 2026-01-12 | Vertex Pharma | N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio |
| AU2022283934A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| CA3221938A1 (fr) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Analogues de tetrahydrofurane substitues utiles en tant que modulateurs de canaux sodiques |
| HRP20260068T1 (hr) | 2021-06-04 | 2026-02-27 | Vertex Pharmaceuticals Incorporated | Čvrsti farmaceutski oblici i režimi doziranja koji obuhvaćaju (2r,3s,4s,5r)-4-[[3-(3,4-difluor-2-metoksifenil)-4,5-dimetil-5-(trifluormetil)tetrahidrofuran-2-karbonil]amino]piridin-2-karboksamid |
| WO2022256842A1 (fr) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Tétrahydrofuranes à substitution hydroxy et (halo)alkoxy utiles en tant que modulateurs de canaux sodiques |
| US20240400544A1 (en) | 2021-06-04 | 2024-12-05 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| UY39882A (es) | 2021-08-02 | 2023-06-15 | Eurofarma Laboratorios S A | COMPUESTOS NACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS |
| AR126669A1 (es) | 2021-08-02 | 2023-11-01 | Eurofarma Laboratorios S A | COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS |
| EP4426290A4 (fr) * | 2021-11-02 | 2025-10-08 | Schedule 1 Therapeutics Inc | Utilisation de compositions de cannabinoïdes pour traiter la douleur associée à une neuropathie des petites fibres |
| CA3256248A1 (fr) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Composés hétéroaryles pour le traitement de la douleur |
| US20230382910A1 (en) | 2022-04-22 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CA3257285A1 (fr) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Composés hétéroaryles pour le traitement de la douleur |
| WO2023205463A1 (fr) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Composés hétéroaryles pour le traitement de la douleur |
| JP2025516005A (ja) | 2022-04-25 | 2025-05-23 | サイトワン セラピューティクス インコーポレイテッド | 疼痛の処置のためのｎａｖ１．８の二環式複素環アミド阻害剤 |
| WO2024123815A1 (fr) | 2022-12-06 | 2024-06-13 | Vertex Pharmaceuticals Incorporated | Procédé de synthèse de modulateurs de tétrahydrofurane substitués de canaux sodiques |
| EP4660182A1 (fr) | 2023-01-30 | 2025-12-10 | Eurofarma Laboratórios S.A. | Composés aryle pyridines inhibiteurs de nav 1.7 et/ou de nav 1.8, leurs procédés d'obtention, compositions, utilisations, méthodes de traitement et trousses |
| PY2404641A (es) | 2023-01-30 | 2024-10-03 | Eurofarma Laboratorios S A | COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y SUS KITS |
| WO2024159287A1 (fr) | 2023-01-30 | 2024-08-08 | Eurofarma Laboratórios S.A. | Hydoxymates inhibiteurs de nav 1.7 et/ou de nav 1.8, leurs procédés d'obtention, compositions, utilisations, méthodes de traitement et trousses |
| PY2405420A (es) | 2023-01-30 | 2024-11-14 | Eurofarma Laboratorios S A | Amidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de los mismos y kits |
| PY2404093A (es) | 2023-01-30 | 2024-10-03 | Eurofarma Laboratorios S A | Hidrazidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de los mismos y kits |
| WO2025090465A1 (fr) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Composés hétéroaryle pour le traitement de la douleur |
| WO2025090480A1 (fr) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Composés hétéroaryles pour le traitement de la douleur |
| WO2025090516A1 (fr) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Procédés de préparation de composés pour le traitement de la douleur et de formes solides de ceux-ci |
| WO2025090511A1 (fr) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Procédés de préparation de modulateurs de canaux sodiques et formes solides de ceux-ci pour le traitement de la douleur |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
| WO2025160286A1 (fr) | 2024-01-24 | 2025-07-31 | Siteone Therapeutics, Inc. | 2-aryl cycloalkyle et inhibiteurs d'hétérocycloalkyle de nav1.8 pour le traitement de la douleur |
| US20260001877A1 (en) | 2024-06-28 | 2026-01-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2026013449A2 (fr) | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Composés dérivés d'oxazolidone et leur utilisation dans le traitement de la douleur chronique et aiguë |
| WO2026030525A1 (fr) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Formes galéniques et schémas posologiques de zilvétrigine pour le traitement de la douleur |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| PT1104760E (pt) * | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios |
| AU2001275881B2 (en) | 2000-07-10 | 2006-04-06 | Vertex Pharmaceuticals (San Diego) Llc | Ion channel assay methods |
| JP2003034671A (ja) | 2001-05-17 | 2003-02-07 | Nippon Nohyaku Co Ltd | ベンズアミド誘導体及び農園芸用薬剤並びにその使用方法 |
| ATE448784T1 (de) | 2002-02-14 | 2009-12-15 | Pharmacia Corp | Substituierte pyridinone als modulatoren für p38 map kinase |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| EP1673357A2 (fr) | 2003-08-08 | 2006-06-28 | Vertex Pharmaceuticals Incorporated | Compositions utilisees comme inhibiteurs de canaux sodium voltage dependants |
| AU2005266090A1 (en) | 2004-07-23 | 2006-02-02 | Pfizer Inc. | Pyridine derivatives |
| EP1934201A1 (fr) * | 2005-10-06 | 2008-06-25 | Auspex Pharmaceuticals Inc. | Inhibiteurs deutériés d'atpase h+,k+ gastrique ayant des propriétés thérapeutiques renforcées |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| EP2004596A2 (fr) | 2006-04-11 | 2008-12-24 | Vertex Pharmaceuticals Incorporated | Compositions utiles en tant qu'inhibiteurs de canaux sodiques sensibles a la tension |
| WO2008060789A2 (fr) | 2006-10-12 | 2008-05-22 | Xenon Pharmaceuticals Inc. | Utilisation de composés de spiro-oxindole comme agents thérapeutiques |
| CA2684105C (fr) | 2007-05-03 | 2011-09-06 | Pfizer Limited | Derives de la pyridine |
| AU2008310660A1 (en) | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| KR20100075631A (ko) | 2007-10-11 | 2010-07-02 | 버텍스 파마슈티칼스 인코포레이티드 | 전압개폐 나트륨 채널의 억제제로서 유용한 아릴 아미드 |
| WO2009049181A1 (fr) | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Amides utiles en tant qu'inhibiteurs de canaux sodiques sensibles au voltage |
| BRPI0919648A2 (pt) | 2008-10-29 | 2015-12-08 | Hoffmann La Roche | novos derivados de fenil amida ou piridil amida e seu uso como agonistas de gpbar1 |
| MX2011006843A (es) | 2008-12-23 | 2011-08-04 | Hoffmann La Roche | Dihidropiridona-amidas como moduladores de p2x7. |
| MX2011006904A (es) | 2008-12-26 | 2011-07-20 | Dainippon Sumitomo Pharma Co | Compuesto heterociclico biciclico novedoso. |
| CN105254557A (zh) | 2009-05-29 | 2016-01-20 | 拉夸里亚创药株式会社 | 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物 |
| TW201103904A (en) | 2009-06-11 | 2011-02-01 | Hoffmann La Roche | Janus kinase inhibitor compounds and methods |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| WO2011026240A1 (fr) | 2009-09-04 | 2011-03-10 | Zalicus Pharmaceuticals Ltd. | Dérivés d'oxopipérazine pour le traitement de la douleur et de l'épilepsie |
| US8598164B2 (en) | 2010-05-06 | 2013-12-03 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| EP2655330B1 (fr) | 2010-12-22 | 2016-02-10 | Purdue Pharma LP | Pyridines substituées en tant que bloqueurs de canaux sodiques |
| KR101923367B1 (ko) | 2011-02-02 | 2018-12-04 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널의 조절제로서의 피롤로피라진―스피로사이클릭 피페리딘 아미드 |
| MX2013009393A (es) | 2011-02-18 | 2013-08-29 | Vertex Pharma | Piperidinamidas cromano-espirociclicas como moduladores de canales de iones. |
| CA2828456C (fr) | 2011-03-03 | 2021-05-04 | Zalicus Pharmaceuticals Ltd. | Inhibiteurs n-benzyl-amino-carboxamide du canal sodique |
| CA2829025A1 (fr) | 2011-03-03 | 2012-09-07 | Concert Pharmaceuticals, Inc. | Derives de composes amino-heteroaryles substitues par des pyrazoles |
| CN103517910B (zh) | 2011-03-14 | 2016-12-14 | 沃泰克斯药物股份有限公司 | 作为离子通道调节剂的吗啉-螺环哌啶酰胺 |
| EP3255041A1 (fr) | 2011-09-02 | 2017-12-13 | Purdue Pharma L.P. | Pyrimidines utilisées comme bloqueurs de canaux sodiques |
| CA2850925C (fr) | 2011-10-26 | 2017-01-10 | Pfizer Limited | Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal de sodium |
| NZ627259A (en) | 2012-01-16 | 2016-12-23 | Vertex Pharma | Pyran-spirocyclic piperidine amides as modulators of ion channels |
| JP6002785B2 (ja) | 2012-02-03 | 2016-10-05 | ファイザー・インク | ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体 |
| WO2013131018A1 (fr) | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Inhibiteurs biaryle du canal sodique |
| DK2822953T5 (en) | 2012-03-06 | 2017-09-11 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
| TWI606048B (zh) | 2013-01-31 | 2017-11-21 | 帝人製藥股份有限公司 | 唑苯衍生物 |
| CA2898653C (fr) | 2013-01-31 | 2021-09-28 | Vertex Pharmaceuticals Incorporated | Amides comme modulateurs des canaux sodiques |
| RS56015B1 (sr) | 2013-01-31 | 2017-09-29 | Vertex Pharma | Piridon amidi kao modulatori natrijumovih kanala |
| RU2683788C2 (ru) | 2013-01-31 | 2019-04-02 | Вертекс Фармасьютикалз Инкорпорейтед | Амиды хинолина и хиназолина, полезные в качестве модуляторов натриевых каналов |
| UA119147C2 (uk) | 2013-07-19 | 2019-05-10 | Вертекс Фармасьютікалз Інкорпорейтед | Сульфонаміди як модулятори натрієвих каналів |
| CA2931550C (fr) | 2013-12-13 | 2023-09-26 | Vertex Pharmaceuticals Incorporated | Promedicaments d'amides de pyridone utiles en tant que modulateurs des canaux sodiques |
| AU2018300150A1 (en) | 2017-07-11 | 2020-01-30 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| US11529337B2 (en) | 2018-02-12 | 2022-12-20 | Vertex Pharmaceuticals Incorporated | Method of treating pain |
-
2018
- 2018-05-16 EP EP18730543.8A patent/EP3625214B1/fr active Active
- 2018-05-16 WO PCT/US2018/032939 patent/WO2018213426A1/fr not_active Ceased
- 2018-05-16 BR BR112019024016A patent/BR112019024016A2/pt active Search and Examination
- 2018-05-16 MA MA049137A patent/MA49137A/fr unknown
- 2018-05-16 US US16/614,015 patent/US11358977B2/en active Active
- 2018-05-16 IL IL270680A patent/IL270680B/en unknown
- 2018-05-16 KR KR1020197037074A patent/KR102714561B1/ko active Active
- 2018-05-16 UA UAA201911875A patent/UA124857C2/uk unknown
- 2018-05-16 MX MX2019013574A patent/MX390793B/es unknown
- 2018-05-16 AU AU2018271110A patent/AU2018271110A1/en not_active Abandoned
- 2018-05-16 JP JP2019563132A patent/JP7104070B2/ja not_active Expired - Fee Related
- 2018-05-16 CN CN201880037064.5A patent/CN110740993B/zh active Active
- 2018-05-16 ES ES18730543T patent/ES2927712T3/es active Active
- 2018-05-16 CA CA3063901A patent/CA3063901A1/fr active Pending
-
2019
- 2019-11-12 CL CL2019003239A patent/CL2019003239A1/es unknown
- 2019-11-18 ZA ZA2019/07619A patent/ZA201907619B/en unknown
- 2019-11-21 CO CONC2019/0013021A patent/CO2019013021A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102714561B1 (ko) | 2024-10-10 |
| AU2018271110A1 (en) | 2019-12-05 |
| US11358977B2 (en) | 2022-06-14 |
| MX2019013574A (es) | 2019-12-18 |
| UA124857C2 (uk) | 2021-12-01 |
| CN110740993B (zh) | 2023-09-01 |
| CL2019003239A1 (es) | 2020-04-17 |
| JP2020519661A (ja) | 2020-07-02 |
| WO2018213426A1 (fr) | 2018-11-22 |
| MX390793B (es) | 2025-03-21 |
| EP3625214B1 (fr) | 2022-07-06 |
| KR20200006128A (ko) | 2020-01-17 |
| CO2019013021A2 (es) | 2020-04-01 |
| BR112019024016A2 (pt) | 2020-06-09 |
| ZA201907619B (en) | 2022-03-30 |
| EP3625214A1 (fr) | 2020-03-25 |
| JP7104070B2 (ja) | 2022-07-20 |
| IL270680B (en) | 2022-06-01 |
| CN110740993A (zh) | 2020-01-31 |
| ES2927712T3 (es) | 2022-11-10 |
| CA3063901A1 (fr) | 2018-11-22 |
| US20210155643A1 (en) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49137A (fr) | Amides de pyridone deutérés et leurs promédicaments utilisés en tant que modulateurs de canaux sodiques | |
| EP3787607A4 (fr) | Compositions de caroténoïdes et leurs utilisations | |
| EP3523294A4 (fr) | Modulateurs de calpain et leurs utilisations thérapeutiques | |
| EP3490565A4 (fr) | Modulateurs de récepteurs de chimiokine et leurs utilisations | |
| MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
| MA49566A (fr) | Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques | |
| DK3668512T3 (da) | Pyruvatkinasemodulatorer og anvendelse deraf | |
| EP3364958A4 (fr) | Modulateurs d'interaction sestrine-gator2 et leurs utilisations | |
| MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
| MA53145A (fr) | Agents de liaison cd123 et leurs utilisations | |
| MA52365A (fr) | Composés et leurs utilisations | |
| MA43529A (fr) | Modulateurs de transport nucléaire et leurs utilisations | |
| MA54567A (fr) | Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma | |
| EP3340988A4 (fr) | Composés inhibiteurs de canaux ioniques, formulations pharmaceutiques, et utilisations | |
| MA52092A (fr) | Composés et leurs utilisations | |
| EP3638251A4 (fr) | Formulations de gel de bisphosphocine et leurs utilisations | |
| MA46901A (fr) | Agents psychotropes et leurs utilisations | |
| EP3353303A4 (fr) | Compositions et méthodes de modulation de l'expression de l'ataxine 3 | |
| EP3774737A4 (fr) | Modulateurs de calpaïne et leurs utilisations thérapeutiques | |
| EP3432859A4 (fr) | Compositions cosmétiques et leurs utilisations | |
| EP3914245A4 (fr) | Modulateurs de mtorc et leurs utilisations | |
| MA43530A (fr) | Modulateurs de transport nucléaire et leurs utilisations | |
| MA46945A (fr) | Exopolysaccharides et leurs utilisations |